DE602008005894D1 - Kondensierte imidazole zur krebsbehandlung - Google Patents
Kondensierte imidazole zur krebsbehandlungInfo
- Publication number
- DE602008005894D1 DE602008005894D1 DE602008005894T DE602008005894T DE602008005894D1 DE 602008005894 D1 DE602008005894 D1 DE 602008005894D1 DE 602008005894 T DE602008005894 T DE 602008005894T DE 602008005894 T DE602008005894 T DE 602008005894T DE 602008005894 D1 DE602008005894 D1 DE 602008005894D1
- Authority
- DE
- Germany
- Prior art keywords
- cancer treatment
- condensed imidazole
- imidazole
- condensed
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1573MU2007 | 2007-08-14 | ||
EP07118733A EP2062893A1 (de) | 2007-10-18 | 2007-10-18 | Fusionierte Imidazole zur Behandlung von Krebs |
PCT/EP2008/060686 WO2009021990A1 (en) | 2007-08-14 | 2008-08-14 | Fused imidazoles for cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602008005894D1 true DE602008005894D1 (de) | 2011-05-12 |
Family
ID=39876840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602008005894T Active DE602008005894D1 (de) | 2007-08-14 | 2008-08-14 | Kondensierte imidazole zur krebsbehandlung |
Country Status (24)
Country | Link |
---|---|
US (2) | US8592591B2 (de) |
EP (1) | EP2176259B1 (de) |
JP (1) | JP5327652B2 (de) |
KR (1) | KR20100049589A (de) |
CN (1) | CN101835776A (de) |
AR (1) | AR067946A1 (de) |
AT (1) | ATE503757T1 (de) |
AU (1) | AU2008288390A1 (de) |
CA (1) | CA2695251C (de) |
CL (1) | CL2008002397A1 (de) |
CR (1) | CR11271A (de) |
DE (1) | DE602008005894D1 (de) |
DO (1) | DOP2010000057A (de) |
EA (1) | EA201000297A1 (de) |
EC (1) | ECSP109965A (de) |
MA (1) | MA31609B1 (de) |
MX (1) | MX2010001745A (de) |
PA (1) | PA8793301A1 (de) |
PE (1) | PE20090596A1 (de) |
SV (1) | SV2010003482A (de) |
TN (1) | TN2010000071A1 (de) |
TW (1) | TW200924761A (de) |
UY (1) | UY31292A1 (de) |
WO (1) | WO2009021990A1 (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7652133B2 (en) * | 2006-10-19 | 2010-01-26 | Takeda Pharmaceutical Company Limited | Indole compound |
CL2008002397A1 (es) * | 2007-08-14 | 2009-09-25 | Bayer Schering Pharma Ag | Compuestos derivados de imidazoles biciclicos fusionados; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar neoplasia benigna o maligna. |
GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
CN102124009B (zh) | 2008-07-08 | 2014-07-23 | 因特利凯公司 | 激酶抑制剂及其使用方法 |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
ES2435804T3 (es) * | 2009-02-13 | 2013-12-23 | Bayer Intellectual Property Gmbh | Pirimidinas condensadas como inhibidores de Akt |
AU2010226490A1 (en) | 2009-03-20 | 2011-10-06 | Amgen Inc. | Inhibitors of PI3 kinase |
JPWO2010125799A1 (ja) | 2009-04-27 | 2012-10-25 | 塩野義製薬株式会社 | Pi3k阻害活性を有するウレア誘導体 |
EP2467141B1 (de) | 2009-08-17 | 2018-10-31 | Intellikine, LLC | Heterocyclische verbindungen und ihre verwendung |
JP5641664B2 (ja) | 2009-10-30 | 2014-12-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | イミダゾ[1,2−b]ピリダジン誘導体およびPDE10阻害剤としてのそれらの使用 |
CN102725292A (zh) * | 2009-11-02 | 2012-10-10 | 雅培制药有限公司 | 作为用于多靶激酶抑制的新构建物的咪唑并吡啶化合物 |
ES2627703T3 (es) * | 2010-01-22 | 2017-07-31 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | Inhibidores de PI3·quinasa |
UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
CN103097384B (zh) * | 2010-07-12 | 2017-02-15 | 拜耳知识产权有限责任公司 | 取代的咪唑并[1,2‑a]嘧啶和吡啶 |
JP5926727B2 (ja) | 2010-07-28 | 2016-05-25 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換イミダゾ[1,2−b]ピリダジン |
EP2463289A1 (de) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]Pyridazin-Derivate als AS JAK-Hemmer |
DE102011008352A1 (de) * | 2011-01-12 | 2012-07-12 | Merck Patent Gmbh | 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate |
CA2828483A1 (en) | 2011-02-23 | 2012-11-01 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
SG193327A1 (en) * | 2011-04-06 | 2013-10-30 | Taiho Pharmaceutical Co Ltd | Novel imidazo-oxazine compound or salt thereof |
ME02316B (me) * | 2011-04-07 | 2016-06-20 | Bayer Ip Gmbh | Imidazopiridazini kao inhibitori akt kinaze |
EA027418B1 (ru) | 2011-06-27 | 2017-07-31 | Янссен Фармацевтика Нв | ПРОИЗВОДНЫЕ 1-АРИЛ-4-МЕТИЛ[1,2,4]ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ ИХ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ |
EP2554544A1 (de) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1H-)-on-Derivate als JAK-Inhibitoren |
JP6088542B2 (ja) * | 2012-01-10 | 2017-03-01 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | Aktキナーゼ阻害剤としての置換イミダゾピラジン類 |
CA2860724A1 (en) | 2012-01-10 | 2013-07-18 | Bayer Intellectual Property Gmbh | Substituted pyrazolopyrimidines as akt kinase inhibitors |
ES2855575T3 (es) | 2012-06-26 | 2021-09-23 | Janssen Pharmaceutica Nv | Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos |
RU2618423C2 (ru) * | 2012-07-02 | 2017-05-03 | Тайхо Фармасьютикал Ко., Лтд. | Усилитель противоопухолевого эффекта, содержащий имидазооксазиновое соединение |
AU2013289284B2 (en) | 2012-07-09 | 2017-03-30 | Janssen Pharmaceutica Nv | Inhibitors of phosphodiesterase 10 enzyme |
JP6360881B2 (ja) | 2013-03-22 | 2018-07-18 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 触媒的mtorc1/2阻害薬及びオーロラaキナーゼの選択的阻害薬の組合せ |
GB201321732D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
CN107428779A (zh) | 2015-02-27 | 2017-12-01 | 大鹏药品工业株式会社 | 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法 |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
JP2019533022A (ja) * | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス,インコーポレーテッド | 化合物及びその使用 |
CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE361297T1 (de) * | 2000-03-31 | 2007-05-15 | Ortho Mcneil Pharm Inc | Phenyl-substituierte imidazopyridine |
CN1173975C (zh) * | 2000-04-27 | 2004-11-03 | 山之内制药株式会社 | 咪唑并吡啶衍生物 |
EP1622616B1 (de) * | 2003-04-24 | 2011-06-15 | Merck Sharp & Dohme Corp. | Hemmer der akt aktivität |
KR20060034303A (ko) | 2003-07-30 | 2006-04-21 | 라보라토리오스 에스.에이.엘.브이.에이.티., 에스.에이. | 암을 예방하고 치료하기 위한 치환된 이미다조피리미딘 |
EP1737843B1 (de) * | 2004-04-09 | 2011-02-23 | Merck Sharp & Dohme Corp. | Hemmer der akt aktivität |
AU2005290081B2 (en) * | 2004-08-23 | 2010-12-02 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
CN101242834A (zh) * | 2004-12-15 | 2008-08-13 | 默克公司 | Akt活性抑制剂 |
KR20080038278A (ko) | 2005-05-20 | 2008-05-06 | 어레이 바이오파마 인크. | Raf 억제제 화합물 및 그의 사용 방법 |
WO2007025090A2 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
WO2007028051A2 (en) * | 2005-09-02 | 2007-03-08 | Abbott Laboratories | Novel imidazo based heterocycles |
PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
US7530313B2 (en) | 2006-05-12 | 2009-05-12 | Day & Zimmerman, Inc. | Self-destruct fuze delay mechanism |
CL2008002397A1 (es) * | 2007-08-14 | 2009-09-25 | Bayer Schering Pharma Ag | Compuestos derivados de imidazoles biciclicos fusionados; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar neoplasia benigna o maligna. |
-
2008
- 2008-08-14 CL CL2008002397A patent/CL2008002397A1/es unknown
- 2008-08-14 EP EP08787222A patent/EP2176259B1/de active Active
- 2008-08-14 DE DE602008005894T patent/DE602008005894D1/de active Active
- 2008-08-14 CN CN200880103578A patent/CN101835776A/zh active Pending
- 2008-08-14 AU AU2008288390A patent/AU2008288390A1/en not_active Abandoned
- 2008-08-14 CA CA2695251A patent/CA2695251C/en not_active Expired - Fee Related
- 2008-08-14 PA PA20088793301A patent/PA8793301A1/es unknown
- 2008-08-14 TW TW097131067A patent/TW200924761A/zh unknown
- 2008-08-14 AT AT08787222T patent/ATE503757T1/de not_active IP Right Cessation
- 2008-08-14 EA EA201000297A patent/EA201000297A1/ru unknown
- 2008-08-14 WO PCT/EP2008/060686 patent/WO2009021990A1/en active Application Filing
- 2008-08-14 UY UY31292A patent/UY31292A1/es not_active Application Discontinuation
- 2008-08-14 US US12/191,706 patent/US8592591B2/en not_active Expired - Fee Related
- 2008-08-14 JP JP2010520584A patent/JP5327652B2/ja not_active Expired - Fee Related
- 2008-08-14 PE PE2008001379A patent/PE20090596A1/es not_active Application Discontinuation
- 2008-08-14 MX MX2010001745A patent/MX2010001745A/es not_active Application Discontinuation
- 2008-08-14 KR KR1020107003250A patent/KR20100049589A/ko not_active Application Discontinuation
- 2008-08-15 AR ARP080103563A patent/AR067946A1/es unknown
-
2010
- 2010-02-12 EC EC2010009965A patent/ECSP109965A/es unknown
- 2010-02-12 DO DO2010000057A patent/DOP2010000057A/es unknown
- 2010-02-12 TN TNP2010000071A patent/TN2010000071A1/fr unknown
- 2010-02-12 CR CR11271A patent/CR11271A/es not_active Application Discontinuation
- 2010-02-12 MA MA32618A patent/MA31609B1/fr unknown
- 2010-02-12 SV SV2010003482A patent/SV2010003482A/es not_active Application Discontinuation
-
2013
- 2013-11-26 US US14/090,367 patent/US9387204B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DOP2010000057A (es) | 2010-04-15 |
US9387204B2 (en) | 2016-07-12 |
PE20090596A1 (es) | 2009-06-07 |
US20090156604A1 (en) | 2009-06-18 |
TN2010000071A1 (en) | 2011-09-26 |
UY31292A1 (es) | 2009-03-31 |
MX2010001745A (es) | 2010-03-10 |
JP5327652B2 (ja) | 2013-10-30 |
SV2010003482A (es) | 2010-07-06 |
CA2695251A1 (en) | 2009-02-19 |
US20140088110A1 (en) | 2014-03-27 |
CA2695251C (en) | 2016-06-21 |
EP2176259A1 (de) | 2010-04-21 |
CL2008002397A1 (es) | 2009-09-25 |
MA31609B1 (fr) | 2010-08-02 |
WO2009021990A1 (en) | 2009-02-19 |
PA8793301A1 (es) | 2009-04-23 |
CN101835776A (zh) | 2010-09-15 |
JP2010535847A (ja) | 2010-11-25 |
US8592591B2 (en) | 2013-11-26 |
AR067946A1 (es) | 2009-10-28 |
CR11271A (es) | 2010-05-19 |
EP2176259B1 (de) | 2011-03-30 |
ECSP109965A (es) | 2010-03-31 |
EA201000297A1 (ru) | 2010-08-30 |
KR20100049589A (ko) | 2010-05-12 |
AU2008288390A1 (en) | 2009-02-19 |
ATE503757T1 (de) | 2011-04-15 |
TW200924761A (en) | 2009-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602008005894D1 (de) | Kondensierte imidazole zur krebsbehandlung | |
BRPI0810206A2 (pt) | Método de tratar câncer | |
DK2121139T3 (da) | Formulations for cancer treatment | |
BR112012005594A2 (pt) | tratamento de câncer | |
DK3289876T3 (da) | Forbindelser til behandling af cancer | |
IT1391555B1 (it) | Apparato trattamento extracorporeo sangue | |
BRPI0910854A2 (pt) | métodos de tratamento | |
BRPI0920104A2 (pt) | tratamento de soluções ou de águas residuais | |
BRPI0814307A2 (pt) | Sistema de tratamento presbiópico | |
BRPI0912683A2 (pt) | tratamento de tumores metastáticos | |
BRPI1013618A2 (pt) | pirimidinas substituídas para o tratamento de câncer | |
EP2310006A4 (de) | Krebsbehandlung | |
BRPI0922884A2 (pt) | compostos para tratamento de câncer | |
BRPI0909016A2 (pt) | anticorpos úteis para o tratamento do câncer | |
DK2173831T3 (da) | Brøndbehandling | |
DK2452189T3 (da) | Fremgangsmåde til identifikation af forbindelser til behandling af cancer | |
IL238394A0 (en) | Cancer treatment method | |
BRPI0916079A2 (pt) | tratamento de água marinha residual | |
DK2147122T3 (da) | Enzymatisk kræftbehandling | |
BRPI0922367A2 (pt) | enzastaurin para o tratamento de câncer | |
SE0702686L (sv) | Förfarande för säkra transaktioner | |
GB0804496D0 (en) | Treating cancer | |
BRPI0918508A2 (pt) | orto-aminoanilidas para o tratamento de câncer | |
HK1254607A1 (zh) | 用於治療癌症的有機砷化合物 | |
EP2281575A4 (de) | Antikörper zur behandlung von krebs |